Biodexa Shareholders Reverse Course, Approve 1-for-10,000 Reverse Split

summarizeSummary

Biodexa Pharmaceuticals shareholders approved a 1-for-10,000 reverse stock split on July 29, 2026, reversing a prior rejection. Effective July 30, the move is essential for Nasdaq compliance and follows recent dilutive financings.

check_boxKey Events · Corporate Governance and Compliance · BDRX

• Reverse Split Approved

  Shareholders reversed their June 30, 2026 rejection and approved a 1-for-10,000 reverse stock split. Effective July 30, the move reduces outstanding ordinary shares to 51,453,281, equivalent to 1,029,063 ADSs.

• ADS Ratio Adjustment

  The ADS ratio shifts from 1 ADS per 500,000 ordinary shares to 1 ADS per 50 ordinary shares, with no change in proportional ownership.

• Share Issuance Authority Granted

  Directors were authorized to allot ordinary shares on a non-pre-emptive basis, adding potential future dilution.

• Nasdaq Compliance at Stake

  The reverse split is critical for maintaining Nasdaq listing requirements, following a series of highly dilutive offerings in July 2026.

auto_awesomeAnalysis · BDRX · Life Sciences

In a sharp reversal from their June 30, 2026 rejection, Biodexa shareholders approved a 1-for-10,000 reverse stock split on July 29. The split takes effect July 30, slashing outstanding ordinary shares to 51.5 million and resetting the ADS ratio to 1:50—without altering proportional ownership. This approval is pivotal for the company's efforts to maintain its Nasdaq listing and advance its financing strategy, especially after a string of highly dilutive offerings. Adding to the picture, the board also secured authority to issue shares on a non-pre-emptive basis, which introduces potential future dilution risk.